Literature DB >> 10073854

Long-term prospective assessment of left ventricular thrombus in anterior wall acute myocardial infarction and implications for a rational approach to embolic risk.

S Domenicucci1, F Chiarella, P Bellotti, P Bellone, G Lupi, C Vecchio.   

Abstract

To prospectively assess the predictive value of left ventricular (LV) thrombus anatomy for defining the embolic risk after acute myocardial infarction (AMI), 2 comparable groups of patients with a first anterior AMI (group A, 97 thrombolysed patients; group B, 125 patients untreated with antithrombotic drugs [total 222]) underwent prospective serial echocardiography (follow-up 39 +/- 13 months) at different time periods. LV thrombi were detected in 26 patients in group A (27%) and in 71 in group B (57%; p <0.005). Embolism occurred in 12 patients (5.4%; 1 in group A [1%] vs 11% in group B [9%], p < 0.04). At multivariate analysis, thrombus morphologic changes were the most powerful predictor of embolism (p <0.001), followed by protruding shape (p <0.01) and mobility (p <0.02). In patients untreated with thrombolysis, a higher occurrence of thrombus morphologic changes (48% vs 8%, p <0.002) and protruding shape (69% vs 31%, p <0.002) were observed, whereas thrombus mobility was similar in the 2 groups (18% vs 8%, p = NS). Thrombus resolution occurred more frequently in thrombolysed patients (85% vs 56%, p <0.002). Thus, after anterior AMI, changes in LV thrombus anatomy frequently occur and appear the most powerful predictor of embolization. A minor prevalence of thrombus, a more favorable thrombus anatomy, and a higher resolution rate may contribute to reduce embolic risk after thrombolysis.

Entities:  

Mesh:

Year:  1999        PMID: 10073854     DOI: 10.1016/s0002-9149(98)00906-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR.

Authors:  Jonathan W Weinsaft; Han W Kim; Anna Lisa Crowley; Igor Klem; Chetan Shenoy; Lowie Van Assche; Rhoda Brosnan; Dipan J Shah; Eric J Velazquez; Michele Parker; Robert M Judd; Raymond J Kim
Journal:  JACC Cardiovasc Imaging       Date:  2011-07

2.  Long-Term Embolic Outcomes After Detection of Left Ventricular Thrombus by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Imaging: A Matched Cohort Study.

Authors:  Pratik S Velangi; Christopher Choo; Ko-Hsuan A Chen; Felipe Kazmirczak; Prabhjot S Nijjar; Afshin Farzaneh-Far; Osama Okasha; Mehmet Akçakaya; Jonathan W Weinsaft; Chetan Shenoy
Journal:  Circ Cardiovasc Imaging       Date:  2019-11-11       Impact factor: 7.792

3.  Abciximab and left ventricular thrombus formation in early period of acute myocardial infarction treated with successful primary stenting.

Authors:  Marzenna Zielinska; Krzysztof Kaczmarek
Journal:  J Thromb Thrombolysis       Date:  2008-05-04       Impact factor: 2.300

4.  Determinants of left ventricular thrombus formation after primary percutaneous coronary intervention for anterior wall myocardial infarction.

Authors:  LeRoy Elazar Rabbani; Carol Waksmonski; Sohah N Iqbal; Jennifer Stant; Robert Sciacca; Mark Apfelbaum; Osman R Sayan; James Giglio; Shunichi Homma
Journal:  J Thromb Thrombolysis       Date:  2007-06-12       Impact factor: 2.300

5.  Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus.

Authors:  Jonathan W Weinsaft; Raymond J Kim; Michael Ross; Daniel Krauser; Shant Manoushagian; Troy M LaBounty; Matthew D Cham; James K Min; Kirsten Healy; Yi Wang; Michele Parker; Mary J Roman; Richard B Devereux
Journal:  JACC Cardiovasc Imaging       Date:  2009-08

6.  Relationship of left ventricular thrombus formation and adverse outcomes in acute anterior myocardial infarction in patients treated with primary percutaneous coronary intervention.

Authors:  Qian Zhang; Chun-Mei Wang; Shu-Tian Shi; Hong Chen; Yu-Jie Zhou
Journal:  Clin Cardiol       Date:  2018-11-30       Impact factor: 2.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.